Ref: For Group B Meningococci no vaccine is available as polysacchride capsule of Group B is poorly immunogenic and it is also encephalitogenic due to cross reactive antigen on neural cells.* But recently FDA has approved Serogroup B meningococcal vaccines (Recombinant) - (Bexsero- and Trumenba-. These two, newly licensed serogroup B meningococcal vaccines are an important step forward for controlling serogroup B meningococcal disease, especially in outbreak settings. For outbreaks caused by serogroup B meningococcal disease, vaccination with a serogroup B meningococcal vaccine is recommended for those 10 years or older identified as being at increased risk because of the outbreak.">